MK-2048 is a second-generation integrase strand transfer inhibitor with potent anti-HIV activity; it effectively inhibits wild-type HIV integrase and the R263K mutant with IC50 values of 2.6 nM and 1.5 nM, respectively; it demonstrates antiviral activity against HIV-1 subtype B and C clinical isolates in vitro with EC50 values ranging from 0.3 nM to 148 nM and from 0.7 nM to 33 nM, respectively; it retains activity against raltegravir-resistant Q148K and N155H mutant viruses; it exhibits consistent anti-HIV efficacy in peripheral blood mononuclear cells (PBMCs), macrophages, and C8166 T-lymphocytes with EC50 values of 0.4 nM, 0.9 nM, and 11.5 nM, respectively.